Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 206

1.

Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience.

Nakhlis F, Regan MM, Chun YS, Dominici LS, Caterson S, Bellon JR, Warren L, Yeh ED, Jacene HA, King TA, Overmoyer B.

Breast J. 2019 Aug 25. doi: 10.1111/tbj.13509. [Epub ahead of print]

PMID:
31448540
2.

Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion.

Mamtani A, Nakhlis F, Downs-Canner S, Zabor EC, Morrow M, King TA, Van Zee KJ.

Ann Surg Oncol. 2019 Aug 22. doi: 10.1245/s10434-019-07693-1. [Epub ahead of print]

PMID:
31440931
3.

Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.

Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M.

Ann Surg Oncol. 2019 Oct;26(11):3517-3525. doi: 10.1245/s10434-019-07583-6. Epub 2019 Jul 24.

PMID:
31342389
4.

Strategies for the Diversity-Oriented Synthesis of Macrocycles.

Mortensen KT, Osberger TJ, King TA, Sore HF, Spring DR.

Chem Rev. 2019 Sep 11;119(17):10288-10317. doi: 10.1021/acs.chemrev.9b00084. Epub 2019 Jun 20.

PMID:
31244001
5.

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.

Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W.

NPJ Breast Cancer. 2019 May 30;5:16. doi: 10.1038/s41523-019-0111-0. eCollection 2019.

6.

Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.

Wong SM, Almana N, Choi J, Hu J, Gagnon H, Natsuhara K, Shen AH, DeSantis S, Dominici L, Golshan M, Weiss A, Bellon J, Mittendorf EA, King TA.

Ann Surg Oncol. 2019 Oct;26(11):3502-3509. doi: 10.1245/s10434-019-07517-2. Epub 2019 Jun 21.

PMID:
31228134
7.

Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Laws A, Hughes ME, Hu J, Barry WT, Dominici L, Nakhlis F, Barbie T, Duggan M, Weiss A, Rhei E, Carter K, Nimbkar S, Schnitt SJ, King TA.

Ann Surg Oncol. 2019 Jun 20. doi: 10.1245/s10434-019-07515-4. [Epub ahead of print]

PMID:
31222687
8.

Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy.

Baker GM, King TA, Schnitt SJ.

Adv Anat Pathol. 2019 Jul;26(4):221-234. doi: 10.1097/PAP.0000000000000237.

PMID:
31149907
9.

Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.

Mittendorf EA, King TA.

Ann Surg Oncol. 2019 May;26(5):1173-1175. doi: 10.1245/s10434-019-07240-y. Epub 2019 Feb 24. No abstract available.

PMID:
30798446
10.
11.

Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk.

Weiss A, Grossmith S, Cutts D, Mikami SA, Suskin JA, Graichen MK, Rojas NA, Pace LE, Joyce E, Rhei E, Scheib R, Bychkovsky B, Garber JE, Morganstern D, King TA.

Breast Cancer Res Treat. 2019 May;175(1):229-237. doi: 10.1007/s10549-018-05116-5. Epub 2019 Jan 21.

PMID:
30666540
12.

Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?

Coopey SB, Kartal K, Li C, Yala A, Barzilay R, Faulkner HR, King TA, Acevedo F, Garber JE, Guidi AJ, Hughes KS.

Breast Cancer Res Treat. 2019 May;175(1):1-4. doi: 10.1007/s10549-018-05117-4. Epub 2019 Jan 21. Review.

PMID:
30666539
13.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
14.

Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS).

Punglia RS, Bifolck K, Golshan M, Lehman C, Collins L, Polyak K, Mittendorf E, Garber J, Hwang SE, Schnitt SJ, Partridge AH, King TA.

JNCI Cancer Spectr. 2018 Nov;2(4):pky063. doi: 10.1093/jncics/pky063. Epub 2018 Dec 27.

15.

Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.

Heng YJ, Wang J, Ahearn TU, Brown SB, Zhang X, Ambrosone CB, de Andrade VP, Brufsky AM, Couch FJ, King TA, Modugno F, Vachon CM, DuPre NC, Garcia-Closas M, Troester MA, Hunter DJ, Eliassen AH, Tamimi RM, Hankinson SE, Beck AH.

Breast Cancer Res Treat. 2019 Feb;173(3):667-677. doi: 10.1007/s10549-018-5034-1. Epub 2018 Nov 1.

PMID:
30387004
16.

Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ.

Nakhlis F, Harrison BT, Giess CS, Lester SC, Hughes KS, Coopey SB, King TA.

Ann Surg Oncol. 2019 Jan;26(1):55-61. doi: 10.1245/s10434-018-6937-0. Epub 2018 Oct 25.

PMID:
30362065
17.

Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.

Lee JY, Schizas M, Geyer FC, Selenica P, Piscuoglio S, Sakr RA, Ng CKY, Carniello JVS, Towers R, Giri DD, de Andrade VP, Papanastasiou AD, Viale A, Harris RS, Solit DB, Weigelt B, Reis-Filho JS, King TA.

Clin Cancer Res. 2019 Jan 15;25(2):674-686. doi: 10.1158/1078-0432.CCR-18-1103. Epub 2018 Sep 5.

PMID:
30185420
18.

Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy.

Laws A, Anderson K, Hu J, McLean K, Novak L, Dominici LS, Nakhlis F, Carty M, Caterson S, Chun Y, Duggan M, Barry W, Connell N, Golshan M, King TA.

Ann Surg Oncol. 2018 Nov;25(12):3548-3555. doi: 10.1245/s10434-018-6696-y. Epub 2018 Aug 20.

PMID:
30128903
19.

Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.

Natsuhara KH, Losk K, King TA, Lin NU, Camuso K, Golshan M, Pochebit S, Brock JE, Bunnell CA, Freedman RA.

Oncologist. 2019 May;24(5):595-602. doi: 10.1634/theoncologist.2018-0154. Epub 2018 Aug 3.

PMID:
30076279
20.

Chronic Pain After Breast Surgery: A Prospective, Observational Study.

Spivey TL, Gutowski ED, Zinboonyahgoon N, King TA, Dominici L, Edwards RR, Golshan M, Schreiber KL.

Ann Surg Oncol. 2018 Oct;25(10):2917-2924. doi: 10.1245/s10434-018-6644-x. Epub 2018 Jul 16.

PMID:
30014456

Supplemental Content

Loading ...
Support Center